(See the editorial commentary by Sousa et al on pages 1361-3.) Listeriolysin O (LLO), an essential virulence determinant of Listeria monocytogenes, is a pore-forming toxin whose primary function is to facilitate cytosolic bacterial replication by breaching the phagosomal membranes, which is critical for the pathogen to evade host immune recognition. The critical role of LLO in the virulence of L. monocytogenes renders it an ideal target for designing novel antivirulence therapeutics. We found that fisetin, a natural flavonoid without antimicrobial activity, is a potent antagonist of LLO-mediated hemolysis. Fisetin effectively inhibits L. monocytogenes infection in both tissue culture and animal infection models. Molecular modeling and mutational analysis revealed that fisetin directly engages loop 2 and loop 3 of LLO, leading to the blockage of cholesterol binding and the reduction of its oligomerization, thus inhibiting its hemolytic activity. Our results establish fisetin as an effective antitoxin agent for LLO, which can be further developed into novel therapeutics against infections caused by L. monocytogenes.
Listeria monocytogenes, the etiologic agent of listeriosis, is a ubiquitous intracellular bacterial pathogen that can grow in conditions normally used for food conservation, such as refrigerator temperature (4°C-10°C), high salt concentrations, and high or low pH [1] . Ingestion of food contaminated with L. monocytogenes can lead to listeriosis, an infection characterized by multiple manifestations such as bacteremia, meningitis, and gastroenteritis in humans or animals [2] . The high fatality rates (25%-30%, despite early antibiotic therapy) associated with listeriosis make L. monocytogenes one of the most deadly foodborne pathogens and an important public health challenge [3] . For example, the 2011 outbreak in the United States was one of the most devastating foodborne infections in the country, affecting 28 states for about 100 days and leading to 146 illnesses and 30 deaths [4] .
To complete its intracellular life cycle, L. monocytogenes uses a number of surface proteins and virulence factors to subvert host cell functions and gain access to the cytosol, including internalin, listeriolysin O (LLO), phospholipase C, and ActA, which function at different phases of the infection to facilitate the bacterial entry, phagosomal escape, and cell-cell spread [5] . Among these, the destabilization and disruption of the vacuolar membranes mostly are mediated by LLO, a member of the cholesterol-dependent cytolysin family [6] . Encoded by the hly gene, this toxin is an essential virulence factor of L. monocytogenes. Inactivation of the hly gene results in the loss of hemolytic activity and the inability to escape from the bacterial vacuole, and the mutant is absolutely nonvirulent in the mouse infection model [7, 8] . Purified LLO encapsulated into pH-sensitive liposomes is sufficient to mediate lysis of endocytic compartments [9] . Remarkably, expression of LLO in Bacillus subtilis had been shown to allow this nonpathogenic soil bacterium to disrupt the phagosomal membrane and grow robustly in the cytoplasm of macrophages [10] , further pointing to the importance of this toxin in the infection of mammalian cells. Besides membrane lysis, numerous studies have established LLO as a multifunctional protein involved in diverse aspects of the interactions between L. monocytogenes and vertebrate hosts [11, 12] .
Interactions with cholesterol, the receptor for most cholesteroldependent cytolysins at the membrane surface, initiate a cascade of secondary and tertiary structural changes in the water-soluble monomer of LLO, which ultimately leads to the formation of pores in the membrane of host cells. Interference with any of these 3 major stages (membrane binding, oligomerization, and formation of the transmembrane β-barrel pore) often leads to the abolishment of the cytolytic function of LLO, resulting in the retention of L. monocytogenes within its phagosome [12] .
The many essential roles of LLO in the pathogenicity of L. monocytogenes suggest that targeting this toxin is a potentially effective strategy against infections caused by this bacterium. This antivirulence therapeutic strategy differs from conventional strategies, which often disrupt essential bacterial cellular functions, such as cell wall synthesis, DNA replication, or protein synthesis, and may be less likely to result in antibacterial resistance and the disruption of normal microbial populations [13] . In this study, we discovered that fisetin (FSN), a dietary flavonoid found in many fruits and vegetables [14] , effectively inhibits L. monocytogenes virulence in both tissue culture and animal model infections by interfering with LLO oligomerization.
MATERIALS AND METHODS

Bacterial Strains and Infection
L. monocytogenes strains used in this study were wild-type strains ATCC19115 [15] and EGD, the hly deletion mutant EGDΔhly, and its complementation strain EGDΔhly::hly [16] . Detailed information on bacterial culture and infection is in the Supplementary Materials.
Mice and Tissue Culture
Female BALB/c mice aged 6-8 weeks were purchased from Jilin University Experimental Animal Center and were maintained in accordance with the guidelines of the Jilin University institutional animal care committee. Other materials and methods used are described in the Supplementary Materials.
RESULTS
FSN Antagonizes the Hemolytic Activity of LLO
Earlier studies found that some plant essential oils and disinfectants alleviated the virulence of L. monocytogenes [17, 18] . To identify the active components in these products that are involved in such protection, we screened for plant products capable of inhibiting LLO-induced hemolysis. We found that FSN, a dietary flavonoid ( Figure 1A ) from vegetables and fruits [14] , significantly inhibited the hemolytic activity of L. monocytogenes culture supernatant ( Figure 1B ). Further evaluation using purified recombinant LLO (rLLO) revealed that lysis of red blood cells was significantly inhibited when the compound was added at 1.75 µM and that maximal inhibition was achieved at 7 µM ( Figure 1C ). Under our experimental conditions, the concentration required for 50% inhibition was 1.51 µM, which was about 5-fold lower than that of cholesterol, a known inhibitor of LLO ( Figure 1C ) [19] . These results suggest that FSN antagonizes the hemolytic activity of LLO, probably by protecting the red blood cells or by directly interacting with the toxin. Consistent with this, incubation of FSN at concentrations sufficient for hemolysis inhibition did not detectably affect the expression and stability of LLO by L. monocytogenes or its growth in bacteriological medium ( Figure 1D-F ) . Taken together, our results establish that although FSN has little effect on bacterial physiology, it is capable of effectively inhibiting the hemolytic activity of LLO.
FSN Facilitates the Elimination of Bacteria by Macrophages via Inhibiting Its Escape From the Phagosome
The inhibition of rLLO-induced hemolysis by FSN prompted us to examine the effects of this compound on intracellular bacterial growth. We first examined the effects of FSN on intracellular replication of L. monocytogenes. As expected, the strain deficient in LLO production failed to replicate, but the defect was restored by chromosomal complementation (strain EGDΔhly:: hly). In infections treated with 28 µM FSN, wild-type bacterial growth was reduced by at least 10-fold ( Figure 2A ). However, this protective effect was not observed in HeLa cells, an epithelial cell line in which LLO −/− mutants can escape from the vacuole, grow, and spread among cells [20] , suggesting that the inhibition is due to the effects of FSN on LLO (Figure 2A and 2B). We also found that wild-type L. monocytogenes caused significant cytotoxicity, as measured by the release of lactate dehydrogenase ( Figure 2C ). As expected, the cytotoxicity depended on LLO ( Figure 2C ). Importantly, FSN significantly reduced the cytotoxicity in a dose-dependent manner ( Figure 2C ). Since FSN did not detectably affect the phagocytosis of L. monocytogenes ( Figure 2D and 2E), we determined the effects of FSN on intracellular replication of L. monocytogenes. We first examined the escape of L. monocytogenes from the phagosome. Consistent with earlier results [21] , 2 hours after infection >80% of the wild-type bacteria resided in the cytoplasm (Supplementary Figure 1A ). Further, LLO was essential for such escape because bacteria defective for hly were trapped in the phagosome, with the defect fully restored in the complementation strain (Supplementary Figure 1A) . Consistent with its potential inhibitory effects on LLO activity, FSN resulted in the retention of the wild-type bacteria in the phagosome; only <20% of the bacteria stained positively for actin (ie, were localized in the cytoplasm; Supplementary Figure 1) .
When intracellular bacterial replication was assessed by microscopy 5 hours after infection, robust bacterial replication was observed only in samples infected with the wild-type EGD strain or the Δhly::hly strain ( Figure 3A) . Furthermore, differing from findings for the Δhly mutant, most bacteria of these 2 strains colocalized with F-actin, indicative of cytosolic localization ( Figure 3A) . Importantly, treatment with 28 µM of FSN led to little replication of the wild-type strain, and FSN treatment had no effect on intracellular survival of the Δhly mutant, indicating that the protection by FSN was due to an effect on LLO (Figures 2A and 3A) . Finally, FSN also caused bacterial clearance by macrophages, as significantly fewer live bacteria were detected in FSN-treated samples ( Figure 3B and 3C). Taken together, these results indicate that FSN blocks the escape of L. monocytogenes into the cytosol, leading to the digestion of the bacteria by macrophages.
FSN Effectively Protects Mice From L. monocytogenes Infection
We next analyzed whether similar protection occurs in a mouse infection model. After subcutaneous administration of a single dose of FSN nanoemulsion at 100 mg/kg, FSN was readily detected in mouse plasma, with a maximal concentration of 19.34 µg/mL 15 minutes after injection ( Figure 4A ), indicating that the compound enters the circulation efficiently.
Intravenous inoculation with 2 × 10 6 L. monocytogenes bacteria killed approximately 75% of BALB/c mice within 60 hours. All infected animals died within 84 hours, with a median survival time of 36 hours ( Figure 4B ). As expected, similar infections with the Δhly mutant failed to cause mortality during the same experimental duration ( Figure 4B ). When FSN nanoemulsion was given at 100 mg/kg to mice infected by wild-type bacteria, 26.66% and 43.33% were dead by 60 hours and 84 hours after infection, respectively. Furthermore, FSN-treated mice survived significantly longer than untreated mice (P < .0001; Figure 4B ). Consistent with these findings, a significantly lower bacterial burden was observed in the liver and spleen of these mice ( Figure 4C ). Further, analyses of livers and spleens . Data on spontaneous hemoglobin release in supernatant-free samples were used as negative controls. C, Dose-dependent hemolysis inhibition by FSN. Reactions involving indicated concentrations of FSN were established, and the release of hemoglobin was measured as described in panel B. Data shown are the means ± SD from 3 independent experiments. *P < .05 and **P < .01, by 2-tailed Student t tests. D and E, The effects of FSN on the expression and stability of LLO in culture supernatant. The culture supernatant of relevant bacterial strains was incubated with the indicated amounts of FSN for 4 hours, and the level of LLO was evaluated by immunoblot using an LLO-specific antibody after sodium dodecyl sulfate polyacrylamide gel electrophoresis. E, Western blot of the LLO in culture supernatant that had been incubated without or with 7 µM of FSN for the indicated amount of time at 37°C. Unknown protein (UNP) nonspecifically detected by antibody against LLO was used as loading control. F, EGD was incubated in tryptic soy broth in the presence of various concentrations of FSN, and the growth was monitored over 420 minutes by determining the value at OD 600 at the indicated time point.
from untreated mice 48 hours after infection revealed decreased sizes of both organs and numerous small white necrotic foci with a diameter of 1-4 mm ( Figure 4D ). In FSN-treated mice, such pathology was discernibly alleviated, with only mild congestion ( Figure 4D ). The major histopathological characteristics of the liver tissues of control mice were cell degeneration and numerous spotty necroses; the accumulation of bacteria in the tissues was also evident, whereas tissues from FSN-treated mice displayed only minor inflammatory lesions ( Figure 4E ). In spleens from control mice, lymphocyte depletion and necrosis with congestion in germinal centers were also apparent, sharply differing from the mild inflammation seen in spleens from FSNtreated mice ( Figure 4E ). Consistent with these observations, the levels of cytokines such as interleukin 1β, interleukin 6, and tumor necrosis factor α in organ homogenates of FSNtreated mice were significantly lower than those observed for control mice. Furthermore, FSN treatment did not induce the host immune response ( Figure 4F -H). Taken together, these results indicate that treatment with FSN confers systematic protection against infection by L. monocytogenes in the mouse model.
Identification of the LLO Residues Important for Interacting With FSN
LLO residues important for binding FSN were identified with the molecular mechanics generalized Born surface area (FSN) . A, J774 macrophages were infected with the indicated bacterial strains for 5 hours; bacteria associated with fixed samples were detected with a Listeria-specific antibody followed by a secondary chicken anti-rabbit immunoglobulin G coupled to Alexa Fluor 594. Actin was stained with Alexa 488-conjugated phalloidin. Note the numerous bacteria present in the wild-type infection without FSN treatment and the few bacteria associated with samples treated with 28 µM of FSN, which is similar to infections with the hly-deficient strain (bottom panel). B and C, FSN facilitates the bactericidal activity of macrophages. J774 cells treated with 28 µM of FSN or phosphate-buffered saline were incubated with L. monocytogenes at a multiplicity of infection (MOI) of 2.5 for 5 hours. The lysates of infected cells were exposed to Syto 9 and propidium iodide, which stain live (green) and dead bacteria (red), respectively. Scale bar, 15 µm. Processed samples were inspected using a fluorescence microscope for image acquisition. The ratios of live to dead bacteria were determined by enumerating at least 500 bacteria from each of the 3 samples. Similar results were obtained in at least 3 independent experiments. B, The effects of FSN on the mortality of infected mice. Approximately 2 × 10 6 bacterial cells were inoculated intravenously into groups of BALB/c mice, and the mortality rate was monitored over a 96-hour experimental duration. Kaplan-Meier survival estimates were determined for infected mice treated with FSN 2 hours after infection. Similarly infected mice injected with buffer were used as controls. C, The effects of FSN on the bacterial burden of mice infected by L. monocytogenes. Groups of BALB/c mice were infected intravenously with 4 × 10 5 bacteria of the indicated strains. Systematic infection was evaluated by assessing the number of bacterial cells in the liver and spleen of the infected mice 48 hours after infection. D-E, FSN-treated mice exhibited less pathological abnormalities in livers and spleens. Note the ameliorating effects FSN had on L. monocytogenes-mediated injury in both the liver and spleen (D) and the decreased spot necrosis and accumulation of bacteria in sections of liver specimens from mice that received FSN (E). Scale bar, 100 µm. F-H, The effects of FSN on inflammation in infected mice. The levels of tumor necrosis factor α (TNF-α; F ), interleukin 1β (IL-1β; G), and interleukin 6 (IL-6; H) were evaluated 48 hours after infection in livers and spleens from infected mice. The results shown in panels B-H are representative of the results from 3 independent experiments. *P < .05 and **P < .01. Kaplan-Meier plots and log-rank tests were performed for survival curves, and 2-tailed Student t tests were used for other assays.
(MM-GBSA) method [22, 23] . For clarity, among >20 residues potentially important in the interaction with FSN, we plotted only the 10 with the strongest interaction and calculated their energy contributions ( Figure 5A ). Among these, the L2 region can anchor the right side of FSN, and the L3 region of LLO anchors the 4H-chromen-4-one moiety of FSN ( Figure 5B ).
To validate these predictions, the binding energies between FSN and the I396A and K433A mutants were determined by the MM-GBSA method ( Figure 5C-F ) and fluorescence spectroscopy quenching [24] . The experiment results were highly consistent with those obtained by modeling, all of which indicated the importance of these 2 residues in the interactions Table 1 ). Thus, the information generated by the MD simulation about the LLO-FSN complex is reliable, and these 2 molecules likely engage in a way predicted by the modeling.
Analysis of the interactions between cholesterol and LLO by modeling suggested that cholesterol makes direct contact with the L1 and L2 binding cavity and that a similar interaction occur in residues His398, Val403, and Lys494 ( Figure 6A-C) . The binding of cholesterol to the L1 and L2 region of LLO is critical for the oligomerization of the toxin [19] . The MDsimulated trajectory revealed that the distance between the C α atoms of Gly490 and Gly400 ranges from 1.8 to 3.0 nm, with , and G488A-CHO complex (F ). The histogram chart shows the van der Waals (black), electrostatic (red), solvation (blue), and total (gray) contributions for the complexes. C, E, and G, Predicted binding modes of CHO with the wild-type LLO (C) and the Y402A (E) and G488A (G) mutants of LLO are shown with labels for key residues. H, The distances between the C α atoms of Gly490 and Gly400 as a function of time. The black, red, and green lines represent the distance between the same atoms in free LLO, the LLO-FSN complex, and the LLO-CHO complex, respectively. I-K, Comparison of the distances (in nm) between the C α atoms of Gly490 and Gly400 is shown in the structures of free LLO (I), the LLO-CHO complex (J), and the LLO-FSN complex (K). The average distance of the LLO-CHO complex is 2.35 nm. In the absence of ligand, the average distance between the defined points is 2.41 nm, and in the LLO-FSN complex, the distance is 2.79 nm.
an average distance of 2.41 nm ( Figure 6H and 6I ). This distance was 2.0-2.6 nm in the LLO-cholesterol complex (Figure 6H and 6J) . Notably, in the LLO-FSN complex, the distance ranged from 2.4-3.2 nm, with an average of 2.79 nm ( Figure 6H and 6K ) , suggesting that the conformation of the L1 and L2 binding cavity undergoes a significant shift upon the engagement of FSN. Such shift caused a stretch between these 2 binding cavities and impaired the ability of LLO to interact with cholesterol, leading to lower lytic activity. Indeed, MD simulation analysis of the complex of I396A or K433A with FSN revealed that the average distance between the C α atoms of Gly490 and Gly400 is 2.44 nm and 2.42 nm, Figure 7 . Fisetin (FSN) interferes with the biding of LLO to cholesterol (CHO) and its oligomerization. A, FSN has no influence on the membrane-binding activity of LLO or its mutants. Recombinant LLO pretreated with 56 µM of FSN was incubated with sheep erythrocytes, which were collected by centrifugation before sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the toxin bound to membrane was detected by immunoblotting. Unknown protein (UNP) nonspecifically detected by antibody against LLO was used as a loading control. B, The effect of FSN and CHO on the binding of LLO or its mutants to CHO. Two micrograms of CHO were immobilized on polyvinylidene fluoride membranes before the addition of LLO, the I396A mutant, or the K433A mutant (2 nM per well) into 96-well filtration plates preincubated with various concentrations of FSN or CHO. The binding was evaluated by the retention of LLO or its mutants detected by enzyme-linked immunosorbent assay with anti-His antibody and horseradish peroxidase-conjugated rabbit antimouse immunoglobulin G. Data shown are the mean ± SD from 1 representative experiment done in triplicate out of 3 independently performed experiments. C, FSN reduces the oligomer formed by LLO. Oligomerization of LLO or its mutants pretreated with 28 µM FSN was induced by incubating the protein in a buffer with 428 mM KCl. The formation of oligomers was detected by immunoblot after SDS-PAGE. D, The effects of FSN on the hemolysis induced by LLO and its 2 mutants. After incubation with red blood cells, the release of hemoglobin in each sample was determined and measured as described in Figure 1B . E, Derivatives of the Δhly strain expressing wild-type, the I396A mutant, or the K433A mutant were used to challenge J774 macrophages at a multiplicity of infection of 5, and FSN was added to relevant samples at indicated concentrations. Cytotoxicity was measured by the release of lactate dehydrogenase (LDH). Experiments were performed in triplicate, and similar results were obtained in at least 3 independent experiments. *P < .05 and **P < .01, by 2-tailed Student t tests. Abbreviation: MW, molecular weight.
respectively, which is shorter than that in the LLO-FSN complex. These results suggest that the inhibitory effects of FSN on LLO are greater than that caused by each of the 2 mutations.
FSN Interferes With the Cholesterol-Binding Activity of LLO and Its Oligomerization
The hemolytic activity of LLO is achieved by a series of events, including membrane binding, oligomerization, and the formation of a transmembrane β-barrel pore that directly causes cell lysis [12] . FSN concentrations as high as 56 µM did not detectably affect the binding of LLO or its mutants to cell membranes ( Figure 7A ). Since cholesterol is present in the membrane of erythrocytes [25] , these results are consistent with the fact that binding to the membrane by LLO was not affected by cholesterol [26] .
Similar to earlier observations [27] , the retention of rLLO by cholesterol-coated membranes can be blocked by cholesterol in a dose-dependent manner ( Figure 7B ). As little as 14 µM of FSN almost completely abolished the binding of the toxin to cholesterol; both K433A and I396A mutants were significantly less sensitive to FSN ( Figure 7B) . Notably, the FSN concentration required for effective inhibition of the cholesterol-binding was only one eighth of that of its natural ligand ( Figure 7B ). Finally, pretreatment with FSN led to the formation of significantly lower amount of high-molecular-weight complexes of LLO induced by a high salt concentration ( Figure 7C ), which suggests a decreased amount of oligomers. As predicted by our model, although neither the K433A nor the I396A mutation detectably affected the formation of oligomers by LLO, these mutants were less sensitive to FSN in the inhibition of oligomerization ( Figure 7C ).
We also examined the effects of each of these mutations on the function of LLO and how L. monocytogenes expressing the mutants respond to FSN. The hemolytic activity of both mutants was comparable to that of the wild-type toxin ( Figure 7D ). However, whereas the activity of wild-type LLO was significantly inhibited by 1.75 µM of FSN, neither of these 2 mutants responded to 14 µM of this compound ( Figure 7D ). Interestingly, the sensitivity of rLLO to FSN was more severely affected by the K433A mutation, as inclusion of 28 µM of this compound in the reactions led to only marginal inhibition of its hemolytic activity ( Figure 7D ). When introduced into the chromosome of the Δhly strain, each of these 2 mutated alleles can fully complement the defect of the hly deletion in relevant phenotypes such as cytotoxicity on mammalian cells. The ability to induce cytotoxicity by the strains expressing the mutants cannot be effectively blocked by FSN, which is consistent with the results obtained with recombinant proteins (Figure 7E ). Thus, consistent with prediction derived from our molecular modeling, FSN functions by interfering with the cholesterol-induced oligomerization of LLO.
DISCUSSION
The development of antivirulence agents is considered one of the promising and effective strategies in meeting the challenge posed by widespread drug resistance among bacterial pathogens [13] . Such agents presumably will be more effective for pathogens whose pathogenic traits are determined by ≥1 essential virulence factor. Here we provide evidence that FSN is one such agent with the potential to prevent and treat infections caused by L. monocytogenes by specifically antagonizing the activity of LLO, one of the pathogen's most important virulence factors. FSN effectively inhibited hemolysis induced by LLO. Further, at concentrations effective for blocking virulence in tissue culture and animal infection models, FSN did not detectably affect the vegetative growth of L. monocytogenes or macrophage functions, such as disruption of membrane integrity and phagocytosis, respectively. Finally, FSN interferes with the formation of high-molecular-weight complexes by LLO, which is critical for its membrane insertion activity [12] . Directly targeting LLO apparently will impose less selective pressure on L. monocytogenes and other bacteria associated with the host and will have less chance of inducing the development of resistance. To our knowledge, FSN represents a novel LLO-specific antivirulence agent.
Theoretically, dynamics analysis is the best approach for exploring the mechanism of interaction between a protein and its ligand. Unfortunately, it is very difficult if not impossible to experimentally determine the dynamics of receptor-ligand interactions. Thus, it is gratifying that such interactions can be accurately evaluated by MD simulation [28, 29] , a powerful tool that has been successfully used in the study of the interactions of proteins and their ligands [30] [31] [32] [33] . Our MD simulation and free energy profiles revealed some important insights into the mechanism of inhibition by FSN. Instead of directly competing for the binding site of its natural ligand, cholesterol, FSN appears to engage the L2 and L3 regions of LLO by making contact with Ile396/His398/Tyr402/Val403 and Lys433/Ser434/ Lys435, respectively, at these 2 sites ( Figure 5 and Supplementary Figure 2 ). Based on ligand-residue interaction decomposition, resides Ile396, Val403, and Lys433 were identified as contributing significantly to the binding of LLO to FSN. This prediction was validated by mutational analysis and by the fact that the binding energy between FSN and these mutants was weaker than that observed in the wild-type complex. These results indicate that the information generated about the LLO-FSN complex by the MD simulation is reliable and that these 2 molecules likely engage in a way predicted by the modeling. Analysis of the dynamic trajectory predicted that the engagement of FSN with LLO would cause a shift of the distance between the C α of Gly490 and Gly400 (L1 and L2) and thus affect the binding of cholesterol ( Figure 6 ). In free LLO, L1, L2, and L3 are 3 parallel loop regions, which can swing freely. Because of the binding of which leads to an increase in the distance between L2 and L1 ( Figure 6H-K) . This increase makes LLO less optimal for engaging cholesterol, owing to the low affinity for cholesterol and, consequently, the lower lytic activity. Similar conclusions can be reached by analyzing the complex by MD simulation, which strongly indicates the accuracy and reliability of these modeling methods in the study of the interactions between LLO and FSN or its natural ligand, cholesterol.
Some success has been achieved in the identification of agents effective in treating infections caused by bacterial pathogens, elaborating that toxins are critical for their virulence. For example, antibodies specific for the α-hemolysin are effective in controlling lung injuries caused by Staphylococcus aureus [34] . Similarly, targeting LLO by neutralizing monoclonal antibodies controlled the intracellular growth and virulence of L. monocytogenes [35] . Because of their lower chance of contamination, lower likelihood of triggering an immune reaction, and lower cost in production and maintenance, compounds such FSN should be more advantageous than toxin-specific antibodies. In addition, the capacity of FSN to readily enter and distribute within the host, coupled with its potentially higher stability in the host, make this chemical an ideal leading compound for the development of antivirulence drugs to treat infections caused by L. monocytogenes. Further, it is conceivable that, together with other therapeutic agents, molecules with a novel mode of action will provide better and moreeffective cures. Despite these advantages, as with many antivirulence small molecules several challenges need to be addressed before compounds such as fisetin can be successful used in clinic settings. Further, because mutations in I396 or K433 may make the toxin less susceptible to FSN, extensive use may lead to the selection of naturally occurring mutations in these sites and resistance. However, we envision that the rate of such mutations will be low because this compound does not exert selective pressure on the bacteria. Nevertheless, our results have demonstrated the effectiveness of this natural compound in inhibiting the activity of LLO, which should pave the way for future modification of FSN or the generation of its derivatives to obtain molecules with higher potency against LLO, leading to the development of effective and clinically useful LLO-specific therapeutics.
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